MARK LISKA, M.D.
MOHS-Micrographic Surgery Physician in NORTH FALMOUTH, Massachusetts. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What stands out: MARK LISKA, M.D. reported a CMS MIPS final score of 75 out of 100, below the 83.1 national average, and filed 1,029 Medicare Part D claims in 2023. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.
MARK LISKA, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
MARK LISKA, M.D. at a glance
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Massachusetts
How MOHS-Micrographic Surgery Physician compares to other specialties among Massachusetts providers
MOHS-Micrographic Surgery Physician share within Massachusetts
MOHS-Micrographic Surgery Physician is one of the more visible NUCC categories in Massachusetts
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
MARK LISKA, M.D.'s 2023 MIPS final score plotted against the MOHS-Micrographic Surgery Physician national average
- MIPS Final Score
- 75/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (MOHS-Micrographic Surgery Physician) — 75/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Specialty volume MOHS-Micrographic Surgery Physician US NPIs
75/100 MIPS final score — 8.1 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: MOHS-Micrographic Surgery Physician.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
MARK LISKA, M.D. is a MOHS-Micrographic Surgery Physician provider practicing in NORTH FALMOUTH, Massachusetts, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D.. NPI: 1538191846. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.
MARK LISKA, M.D. appears in the CMS NPPES registry as a MOHS-Micrographic Surgery Physician provider holding M.D. credentials at 37 EDGERTON DRIVE, NORTH FALMOUTH, MA, 02556, with a listed phone of (508) 563-2550. NPI 1538191846 was issued on 07/07/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what LISKA most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 1,029 prescription claims written by this provider, covering 471 Medicare beneficiaries and totaling roughly $835K in drug spend, split 9% brand-name and 91% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 75/100 for the 2023 performance year, compared with the national average of 83.1.
MOHS-Micrographic Surgery Physician is a narrow specialty nationwide, with 1,102 enrolled providers across 52 states and an average of 607 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1538191846 |
|---|---|
| Specialty | MOHS-Micrographic Surgery Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 07/07/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm MARK LISKA, M.D.'s current license status, disciplinary history, and board certifications with the Massachusetts Board of Registration in Medicine in Massachusetts before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MARK LISKA, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$80
Largest payer
Dermavant Sciences, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context — Massachusetts BORIM 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~38K Massachusetts medical licensees in 2023 — they are NOT specific to MARK LISKA, M.D.. To verify MARK LISKA, M.D.'s current license status, search the BORIM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
BORIM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Massachusetts disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Generic-heavy
9% brand-name claims vs 91% generic, on 1,029 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,305
- Total Day Supply
- 35,407
- Brand vs Generic
- 9% brand / 91% generic
- Brand Drug Cost
- $798K
- Generic Drug Cost
- $37K
- Antibiotic Claims
- 104
Patient Demographics
- Average Patient Age
- 78.6 years
- Avg HCC Risk Score
- 1.14
- Gender Split
- 48% female / 52% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
| Drug | Claims |
|---|---|
| Triamcinolone Acetonide | 175 |
| Fluorouracil | 152 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 104 |
| Clobetasol Propionate | 59 |
| Valacyclovir Valacyclovir Hcl | 55 |
| Doxycycline Monohydrate | 45 |
| Mupirocin | 31 |
| Prednisone | 25 |
| Skyrizi Pen Risankizumab-Rzaa | 23 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 23 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
MOHS-Micrographic Surgery Physician Overview
How MARK LISKA, M.D. fits within the MOHS-Micrographic Surgery Physician landscape nationally.
MARK LISKA, M.D.'s 1,029 claims are above the specialty average of 607.
Nearby MOHS-Micrographic Surgery Physician Providers in Massachusetts
Other clinicians with the same primary specialty enrolled in Massachusetts, drawn from the same CMS NPPES roster as LISKA.
Compare MOHS-Micrographic Surgery Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Massachusetts
Frequently Asked Questions
What is MARK LISKA, M.D.'s specialty? ▼
How much does MARK LISKA, M.D. prescribe under Medicare Part D? ▼
What is MARK LISKA, M.D.'s Medicare quality score? ▼
Where is MARK LISKA, M.D. located? ▼
What is MARK LISKA, M.D.'s NPI number? ▼
Does MARK LISKA, M.D. prescribe more brand-name or generic drugs? ▼
How many MOHS-Micrographic Surgery Physician providers are there in the US? ▼
What drugs does MARK LISKA, M.D. prescribe most often? ▼
Does MARK LISKA, M.D. accept Medicare? ▼
How can I verify MARK LISKA, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology